Osteonecrosis of the Jaw in Patients with Bone Metastases Treated with Bisphosphonates: A Retrospective Study
Open Access
- 1 March 2008
- journal article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 13 (3), 330-336
- https://doi.org/10.1634/theoncologist.2007-0159
Abstract
Objective.Bone metastases are a major cause of morbidity in cancer patients. Treatment includes bisphosphonates, which are also associated with avascular osteonecrosis of the jaw (ONJ). Our aim was to evaluate the correlation between bisphosphonates and ONJ. Patients and Methods.Of the 539 patients with bone metastases treated in our department from June 2002 to December 2006 with i.v. bisphosphonates, eight (1.5%) developed ONJ. Results.The eight patients with ONJ had all been given zoledronic acid, and two had also been treated with pamidronic acid. In four of the patients, ONJ was diagnosed during treatment, while in the remaining four it was diagnosed several months after therapy with bisphosphonates had ended. Six of these patients received local noninvasive treatment, of whom five progressed. Two showed apparent autolimitation of the disease. The remaining two patients underwent surgical resection and currently show no signs of relapse. All eight ONJ patients presented with various concomitant risk factors such as paradontopathy, dental extraction, or spontaneous avulsion. Conclusions.Our results show that ONJ can appear months after interruption of treatment and that a surgical approach can be used in suitable cases. Closer cooperation is needed among specialists to define guidelines for the prevention of ONJ in patients with bone metastases.Keywords
This publication has 22 references indexed in Scilit:
- Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasisAnnals of Oncology, 2006
- Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk FactorsJournal of Clinical Oncology, 2006
- Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk FactorsJournal of Clinical Oncology, 2005
- Renal Safety and Efficacy of i.v. Bisphosphonates in Patients with Skeletal Metastases Treated for up to 10 YearsThe Oncologist, 2005
- Osteonecrosis of the Jaw and BisphosphonatesNew England Journal of Medicine, 2005
- Hypercalcemia Associated with CancerNew England Journal of Medicine, 2005
- Thalidomide and immunomodulatory drugs in the treatment of cancerExpert Opinion on Investigational Drugs, 2005
- Ibandronate: A Clinical Pharmacological and Pharmacokinetic UpdateThe Journal of Clinical Pharmacology, 2004
- Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study GroupJournal of Clinical Oncology, 2003
- Metastatic bone disease: clinical features, pathophysiology and treatment strategiesCancer Treatment Reviews, 2001